The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Stem Cell Therapy For Multiple Sclerosis Market In 2026, And How Will Its Value Evolve By 2030?
The stem cell therapy for multiple sclerosis market has experienced considerable growth in recent years. It is projected to expand from $1.82 billion in 2025 to $2.05 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.4%. The expansion observed historically can be attributed to progress in multiple sclerosis treatment research, an increase in the diagnosis rates of autoimmune disorders, the proliferation of stem cell clinical trials, refinement in patient selection protocols, and the increasing presence of specialized neurology centers.
The market for stem cell therapy for multiple sclerosis is projected to undergo significant expansion in the coming years, with its valuation expected to reach $3.24 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.2%. This anticipated growth is primarily fueled by factors such as the increasing availability of long-term efficacy data for stem cell therapies, a rising demand for disease-modifying treatments, the broadening of personalized neurology care, escalating investments in neuro-regenerative research, and enhanced collaboration between hospitals and research institutes. Additionally, the forecast period will be characterized by major trends including the increasing adoption of autologous hematopoietic stem cell transplants, a growing focus on immune system reset therapies, the rising application of mesenchymal stem cells, an increasing use of targeted delivery methods, and improved clinical monitoring and outcome tracking.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30409&type=smp
Which Primary Drivers Are Impacting The Stem Cell Therapy For Multiple Sclerosis Market Growth?
The rising incidence of multiple sclerosis (MS) is anticipated to significantly contribute to the future expansion of the stem cell therapy for multiple sclerosis market. Multiple sclerosis is a chronic autoimmune condition that impacts the central nervous system by harming the protective myelin sheath surrounding nerve fibers, leading to impaired communication between the brain and body and causing symptoms such as fatigue, muscle weakness, and vision issues. The increasing prevalence of MS is primarily attributed to advancements in diagnostic capabilities, as improvements in medical imaging and heightened awareness allow for more accurate and earlier identification of cases, resulting in higher reported numbers. Stem cell therapy for multiple sclerosis helps in repairing damaged myelin, modulating abnormal immune responses, and promoting nerve cell regeneration, thereby aiding in symptom reduction and potentially slowing disease progression. For instance, in May 2024, a report published by the MS Trust, a UK-based organization, indicated that approximately 2.9 million people worldwide are affected by multiple sclerosis, including over 150,000 individuals living with the condition in the UK. Therefore, the increasing prevalence of multiple sclerosis is expected to drive the expansion of the stem cell therapy for multiple sclerosis market.
How Is The Stem Cell Therapy For Multiple Sclerosis Market Categorized Across Its Segment Groups?
The stem cell therapy for multiple sclerosis market covered in this report is segmented –
1) By Type Of Stem Cell: Embryonic Stem Cells, Adult Stem Cells, Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, Hematopoietic Stem Cells
2) By Treatment Approach: Autologous Stem Cell Therapy, Allogeneic Stem Cell Therapy
3) By Delivery Method: Intravenous Injection, Intrathecal Injection, Direct Intraspinal Administration
4) By Application: Relapsing-Remitting Multiple Sclerosis (RRMS), Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Progressive Relapsing Multiple Sclerosis (PRMS)
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Embryonic Stem Cells: Inner Cell Mass Cells, Blastocyst Derived Cells, Totipotent Stem Cells
2) By Adult Stem Cells: Bone Marrow Stem Cells, Neural Stem Cells, Tissue Specific Stem Cells
3) By Induced Pluripotent Stem Cells: Reprogrammed Somatic Cells, Patient Derived Cells
4) By Mesenchymal Stem Cells: Adipose Derived Stem Cells, Umbilical Cord Derived Stem Cells, Bone Marrow Derived Stem Cells
5) By Hematopoietic Stem Cells: Peripheral Blood Stem Cells, Bone Marrow Stem Cells, Umbilical Cord Blood Stem Cells
Which Trends Are Shaping Growth In The Stem Cell Therapy For Multiple Sclerosis Market?
Leading firms within the stem cell therapy for multiple sclerosis market are concentrating on creating novel products, notably adipose-derived mesenchymal stem cells, with the aim of boosting the effectiveness, safety, and restorative capabilities of therapies for individuals suffering from both relapsing-remitting and progressive types of multiple sclerosis. Adipose-derived mesenchymal stem cells (ADMSCs) are multipotent stem cells extracted from fatty tissue, capable of differentiating into various cell types and displaying regenerative and immune-modulating characteristics that prove advantageous in managing autoimmune and neurodegenerative conditions, including multiple sclerosis. As an illustration, in August 2025, the US-based biopharmaceutical firm Hope Biosciences, LLC, unveiled its HB-adMSCs therapy. This treatment employs adipose-derived mesenchymal stem cells delivered through high-dose infusions and subsequent repeat dosing across a 32-week period. This therapy integrates both immunomodulatory and neuroregenerative processes, potentially slowing the advancement of the disease and repairing myelin damage, thereby setting it apart from standard immunosuppressive treatments.
Which Firms Are Influencing Competition In The Stem Cell Therapy For Multiple Sclerosis Market?
Major companies operating in the stem cell therapy for multiple sclerosis market are Sana Biotechnology Inc., Century Therapeutics Inc., Reelabs Private Limited, PlacidWay LLC, MedAccess Guarantee Ltd, Celltex Therapeutics Corporation, CELLTEX THERAPEUTICS CORP, BrainStorm Cell Therapeutics Ltd., Athersys Inc., Advancells Dermaceuticals Private Limited, ImStem Biotechnology Inc., NeuroGenesis Bio Inc., Stem Cell Medicine Ltd., Biotherapy International, R3 Stem Cell, Hope Biosciences LLC, FibroBiologics Inc., Global Institute of Stem Cell Therapy and Research Inc., ProgenCell, Stemwell
Get The Full Stem Cell Therapy For Multiple Sclerosis Market Report:
Which Region Has The Greatest Market Share In The Stem Cell Therapy For Multiple Sclerosis Market?
North America was the largest region in the stem cell therapy for multiple sclerosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stem cell therapy for multiple sclerosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Stem Cell Therapy For Multiple Sclerosis Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Stem Cell Therapy For Multiple Sclerosis Market 2026, By The Business Research Company
Human Embryonic Stem Cells Market Report 2026
https://www.thebusinessresearchcompany.com/report/human-embryonic-stem-cells-global-market-report
Stem Cell Manufacturing Market Report
https://www.thebusinessresearchcompany.com/report/stem-cell-manufacturing-global-market-report
Autologous Stem Cell And Non Stem Cell Based Therapies Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model